I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Ciccarone Center Research
View by Topic
- Antiplatelet Therapy
- ASCVD (Atherosclerotic Cardiovascular Disease)
- Blood Pressure
- Cardiac CT
- Cardiovascular Risk Assessment
- Carotid Atherosclerosis
- Cerebrovascular Disease / Stroke / Cognitive Function
- Cholesterol / Lipids / Statins
- Cigarette Smoking
- Diabetes & Metabolic Syndrome
- Diet & Weight
- Disparities in Care
- Emotional Health
- Endothelial Function
- Erectile Dysfunction
- Exercise and Physical Fitness
- Family History of CVD
- Gender / Cardiovascular Disease in Women
- Heart Failure
- Heart Rate
- Markers of Thrombosis, Myocardial Injury, Wall Stress
- Mobile Health
- Nutrition, Vitamins, Supplements
- PVD – Peripheral Vascular Disease
- Quality of Care
- Renal Disease
- Rheumatoid Arthritis & Collagen Vascular Diseases
- Sleep Disorders
- Stem Cells
- Subclinical Atherosclerosis
- Vascular Imaging
- Vascular Stiffness
View by Journal
- American Heart Journal
- American Journal of Cardiology
- American Journal of Epidemiology
- American Journal of Hypertension
- Annals of Internal Medicine
- Arteriosclerosis, Thrombosis & Vascular Biology
- British Medical Journal
- Clinical Cardiology
- Diabetes Care
- European Heart Journal
- European Journal of Preventive Cardiology
- International Journal of Cardiology
- Journal of Hypertension
- Journal of the American College of Cardiology
- Journal of the American Heart Association
- Journal of the American Medical Association
- Mayo Clinic Proceedings
- New England Journal of Medicine
- PLoS One
View by Year
- Meet the Authors
Gender / Cardiovascular Disease in Women
Health disparities in endocrine disorders: Biological, clinical, and nonclinical factors — an Endocrine Society Scientific Statement.Read on Pubmed
There is little evidence that genetic differences contribute significantly to race/ethnic disparities in the endocrine disorders examined. Multilevel interventions have reduced disparities in diabetes care, and these successes can be modeled to design similar interventions for other endocrine diseases.
Dyslipidemia management in women and men: exploring potential gender differences.
This chapter first examines gender differences in CVD risk factors, then specifically focuses on dyslipidemia in women and the effects of estrogen on CVD risk, and finally addresses treatment guidelines for dyslipidemia.
Rosuvastatin is similarly effective for primary prevention of cardiovascular disease in women as in men
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
The numbers are in – statins for the primary prevention of cardiovascular disease in women.
This study indicates that statin therapy among middle-aged and older women with low LDL-C but above average hsCRP achieves better outcomes than those previously observed in primary prevention trials that were conducted with less potent statins in individuals with overt hyperlipidemia. Clearly, the evidence base for statin therapy in asymptomatic middle-aged and older women with other risk factors is now much more compelling, thanks to the work of Mora and colleagues. We await publication of the formal cost-effectiveness analyses from the landmark JUPITER data set, as well as data on the long-term safety of high-potency statin therapy. In the meantime, clinicians will undoubtedly use the data by Mora et al to prescribe statin therapy much earlier for women who meet the entry criteria of the JUPITER study, and this change will improve cardiovascular outcomes in women.
Sex steroid hormone concentrations and risk of death in U.S. men.
Men with low free and bioavailable testosterone levels may have a higher risk of mortality within 9 years of hormone measurement. Future studies should be conducted to fully characterize the association of low free and bioavailable testosterone concentrations and mortality in men and to describe the mechanism underlying the association.
Noninvasive assessment of gender differences in coronary plaque composition with multidetector computed tomographic angiography.
Few data are available that show gender differences in plaque morphology and composition. This report aims to assess the differences in coronary plaque burden and composition in a noninvasive manner between women and men using multidetector computed tomographic angiography. Results show that gender differences exist, not only in the atherosclerotic disease burden, but also in the underlying plaque composition. Women tended to have more exclusively noncalcified plaque and were less likely to have calcified or mixed plaques compared to men. Future studies are needed to elucidate whether these underlying differences in plaque composition might explain the reduced risk of cardiac events in women.
Effect of Beta-blocker therapy on rehospitalization rates in women versus men with heart failure and preserved ejection fraction.
Beta blockers are empirically used in many patients with heart failure (HF) and preserved ejection fraction (HFpEF) because they allow more time for diastolic filling and because they improve outcomes in patients with systolic HF. However, recent data suggest that impaired chronotropic and vasodilator responses to exercise, which can worsen with beta blockade, may play a key role in the pathophysiology of HFpEF. We prospectively examined the association between beta-blocker therapy after hospitalization for decompensated HF and HF rehospitalization at 6 months in 66 consecutive patients with HFpEF (71 +/- 13 years old, 68% women, 42% Black). Subjects were stratified based on receiving (BB+; 15 men, 28 women) or not receiving (BB-) beta-blockers at hospital discharge. In men, HF rehospitalization occurred less frequently in the BB+ than in the BB- group, albeit nonsignificantly (20% vs 50%, p = 0.29). In women, HF rehospitalization occurred more frequently in the BB+ than in the BB- group (75% vs 18%, p <0.001). In univariate analyses, discharge beta-blocker was associated with HF rehospitalization in women (odds ratio [OR] 14.00, 95% confidence interval [CI] 3.09 to 63.51, p = 0.001), but not in men (OR 0.25, 95% CI 0.03 to 1.92, p = 0.18). In a forward logistic regression model that offered all univariate predictors of HF rehospitalization, discharge beta blocker remained an independent predictor of HF rehospitalization in women (OR 11.06, 95% CI 1.98 to 61.67, p = 0.006). In conclusion, this small observational study suggests that beta-blocker therapy may be associated with a higher risk of HF rehospitalization in women with HFpEF. The risks and benefits of beta-blocker therapy in patients with HFpEF should be evaluated in randomized, controlled trials.
Gender differences in coronary plaque composition by coronary computed tomography angiography.
In this population of asymptomatic middle-aged Korean individuals, males had a significantly greater burden of mixed coronary artery plaques (MCAP) and calcified arterial plaques (CAP). Future studies will determine whether these differences contribute to the accelerated cardiovascular risk observed in men.